Cytokinetics, Inc. (CYTK)
71.40
+0.49
(+0.69%)
USD |
NASDAQ |
Sep 01, 16:00
71.50
+0.10
(+0.14%)
After-Hours: 20:00
Cytokinetics Research and Development Expense (Annual) : 405.90M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 405.90M |
| December 31, 2024 | 329.88M |
| December 31, 2023 | 318.23M |
| December 31, 2022 | 232.41M |
| December 31, 2021 | 150.30M |
| December 31, 2020 | 95.12M |
| December 31, 2019 | 84.83M |
| December 31, 2018 | 89.14M |
| December 31, 2017 | 90.30M |
| December 31, 2016 | 64.40M |
| December 31, 2015 | 46.40M |
| Date | Value |
|---|---|
| December 31, 2014 | 44.43M |
| December 31, 2013 | 49.45M |
| December 31, 2012 | 35.64M |
| December 31, 2011 | 37.18M |
| December 31, 2010 | 38.01M |
| December 31, 2009 | 39.84M |
| December 31, 2008 | 53.95M |
| December 31, 2007 | 53.39M |
| December 31, 2006 | 49.22M |
| December 31, 2005 | 40.57M |
| December 31, 2004 | 39.88M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Bristol Myers Squibb Co. | 9.492B |
| Krystal Biotech, Inc. | 52.32M |
| Ionis Pharmaceuticals, Inc. | 913.18M |
| Vertex Pharmaceuticals, Inc. | 3.754B |
| Alnylam Pharmaceuticals, Inc. | 1.320B |